AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RACE ONCOLOGY LTD

2.100

0.000

Volume:65.57K

Turnover:138.38K

Market Cap:411.74M

PE:-38.85

High:2.160

Open:2.100

Low:2.030

Close:2.100

52wk High:4.900

52wk Low:1.180

Shares:196.07M

Float Shares:121.21M

Volume Ratio:0.93

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.054

EPS(LYR):-0.028

ROE:-42.40%

ROA:-21.91%

PB:17.47

PE(LYR):-75.63

Loading ...

Overview Company News Filings

Racura Oncology Ltd - Cpacs Trial Cleared to Escalate to Next Rc220 Dose Level

THOMSON REUTERS

ASX Penny Stocks To Watch In May 2026

Simply Wall St.

Racura Oncology Ltd-Racura Oncology Options Expiry Reminder

THOMSON REUTERS

Racura says (E,E)-bisantrene silences c-MYC via G-quadruplex DNA binding in preclinical studies

Racura Oncology Says Funding Sufficient for Activities Through 2027

MT Newswires Live

Racura Oncology, University of Wollongong Win New South Wales Government Funding for Cancer Study

MT Newswires Live

Racura Oncology Ltd-Racura and Wollongong Uni Granted Nsw Techvoucher

THOMSON REUTERS

Racura Oncology Says First Patient Recruited to Phase 1 HARNESS-1 Cancer Drug Trial

MT Newswires Live

BUZZ-Australia's Racura Oncology gains on Purdue University cancer study collab

Why EBR, EOS, Racura, and Woodside shares are rising today

Racura Oncology Says Recruitment of First Trial Group in Phase One Advanced Solid Tumors Clinical Trial Completed, Shares Jump 12%

MT Newswires Live

Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?

Racura Oncology Secures Governance Approval For Phase One Trial Testing Its Proprietary Formulation For Non-Small Cell Lung Cancer Treatment

MT Newswires Live

Monday’s HotCopper trends: Elixir, Lynas, Racura, and other daily topics | March 16

The Market Herald

BRIEF-Racura Oncology Receives Governance Approval For Harness-1 Phase 1 Trial Of Rc220

Racura Oncology - Receives Governance Approval for Harness-1 Phase 1 Trial of Rc220

THOMSON REUTERS

Racura Oncology Develops Blood Test to Assess Potential of Proprietary Formulation of Anticancer Drug

MT Newswires Live

Racura Oncology Proposes Selective Buyback, Cancellation Of Shares After Administrative Oversight in Issuance

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/RAC.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","market":"AU","secType":"STK","nameCN":"RACE ONCOLOGY LTD","latestPrice":2.1,"timestamp":1787292720000,"preClose":2.1,"halted":0,"volume":65569,"delay":0,"changeRate":0,"nameEN":"RACE ONCOLOGY LTD","floatShares":121205750,"shares":196068940,"eps":-0.054053,"marketStatus":"Not Yet Opened","change":0,"latestTime":"08-21 16:12:00 AEST","open":2.1,"high":2.16,"low":2.03,"amount":138375,"amplitude":0.061905,"askPrice":2.12,"askSize":1888,"bidPrice":2.06,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.054053,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":2.1,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.9282791832858144,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAC.AU","preClose":2.1,"auctionPrice":2.1,"auctionVolume":220,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292600775}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","floatShares":121205750,"roa":"-21.91%","roe":"-42.40%","lyrEps":-0.027765,"volumeRatio":0.9282791832858144,"shares":196068940,"dividePrice":0,"high":2.16,"amplitude":0.061905,"preClose":2.1,"low":2.03,"week52Low":1.18,"pbRate":"17.47","psRate":"118.43","week52High":4.9,"institutionHeld":0,"latestPrice":2.1,"committee":0.4518,"eps":-0.054053,"divideRate":0,"volume":65569,"delay":0,"ttmEps":-0.054053,"open":2.1,"prevYearClose":2.73,"prevWeekClose":1.995,"prevMonthClose":1.95,"prevQuarterClose":2.22,"fiveDayClose":1.995,"twentyDayClose":2.05,"sixtyDayClose":2.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAC.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635374722","title":"Racura Oncology Ltd - Cpacs Trial Cleared to Escalate to Next Rc220 Dose Level","url":"https://stock-news.laohu8.com/highlight/detail?id=2635374722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635374722?lang=en_us&edition=fundamental","pubTime":"2026-05-15 07:05","pubTimestamp":1778799917,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nFWN41R1MG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634265999","title":"ASX Penny Stocks To Watch In May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2634265999","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634265999?lang=en_us&edition=fundamental","pubTime":"2026-05-12 10:05","pubTimestamp":1778551508,"startTime":"0","endTime":"0","summary":"The Australian market is experiencing a rare uptick, with shares set to rise amid ongoing U.S.-Iran negotiations and anticipation of Jim Chalmers' ambitious federal budget. Despite the vintage connotation of \"penny stocks,\" these smaller or newer companies continue to offer intriguing opportunities for growth at lower price points. When backed by solid financials, penny stocks can present a compelling investment case, combining potential value and growth that may be overlooked in larger firms.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice1-main-header/1585186555515","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice1-main-header/1585186555515"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-erm/emmerson-resources-shares/news/asx-penny-stocks-to-watch-in-may-2026-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-erm/emmerson-resources-shares/news/asx-penny-stocks-to-watch-in-may-2026-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RPL.AU","CLX.AU","BK7016","BK7508","MXI.AU","BK7132","BK7062","BK7104","BK7506","AMA.AU","BK7012","BK7067","BK7058","PPS.AU","BK7503","BK7064","IRI.AU","ERM.AU","EDU.AU","BK7061","WAF.AU","BK7077","OBM.AU","KYP.AU","RAC.AU","GWA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633446105","title":"Racura Oncology Ltd-Racura Oncology Options Expiry Reminder","url":"https://stock-news.laohu8.com/highlight/detail?id=2633446105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633446105?lang=en_us&edition=fundamental","pubTime":"2026-05-08 07:09","pubTimestamp":1778195350,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUE35WWPR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633118227","title":"Racura says (E,E)-bisantrene silences c-MYC via G-quadruplex DNA binding in preclinical studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2633118227","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633118227?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:14","pubTimestamp":1778066095,"startTime":"0","endTime":"0","summary":"Racura Oncology disclosed preclinical findings that clarify primary mechanism behind (E,E)-bisantrene, shifting clinical strategy around its lead asset.Results were presented at AACR Annual Meeting 2026, showing drug binds and stabilizes G-quadruplex structures in c-MYC promoter, leading to suppression of c-MYC expression.Study points to broad anticancer activity across multiple cancer models, supporting positioning of RC220 as a MYC-focused therapy.Programs cited include Phase 3 in acute myeloid leukemia, Phase 1a/b in EGFR-mutant non-small cell lung cancer, plus Phase 1a/b combination study with doxorubicin targeting cardioprotection alongside anticancer activity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Racura Oncology Ltd. pu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL8QFtHF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631050143","title":"Racura Oncology Says Funding Sufficient for Activities Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2631050143","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631050143?lang=en_us&edition=fundamental","pubTime":"2026-04-30 14:05","pubTimestamp":1777529132,"startTime":"0","endTime":"0","summary":"Racura Oncology  said it ended the fiscal third quarter with a cash balance of about AU$19.4 million and is in a strong position to finance activities through 2027, according to a Thursday filing with the Australian bourse.The early conversion of options gave the company an additional AU$1.4 million of funding, per the filing.Racura Oncology said more than 81% of spending during the March quarter, or about AU$2.4 million, went toward research and development and drug manufacturing activities.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631554010","title":"Racura Oncology, University of Wollongong Win New South Wales Government Funding for Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2631554010","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631554010?lang=en_us&edition=fundamental","pubTime":"2026-04-29 11:30","pubTimestamp":1777433412,"startTime":"0","endTime":"0","summary":"Racura Oncology  and the University of Wollongong secured funding under the New South Wales government's TechVouchers program to study the efficacy of (E,E)-bisantrene for certain types of breast and ovarian cancers, according to a Wednesday filing with the Australian bourse.A collaboration between Racura and the University aims to produce preclinical evidence for the development of RC220 as a new targeted therapy, per the filing.Results from the collaboration are expected to come out over the next 12 months.Racura Oncology shares gained 2% in recent Wednesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","RAC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631537193","title":"Racura Oncology Ltd-Racura and Wollongong Uni Granted Nsw Techvoucher","url":"https://stock-news.laohu8.com/highlight/detail?id=2631537193","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631537193?lang=en_us&edition=fundamental","pubTime":"2026-04-29 07:11","pubTimestamp":1777417863,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nTUE5RWJ7S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623723443","title":"Racura Oncology Says First Patient Recruited to Phase 1 HARNESS-1 Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623723443","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623723443?lang=en_us&edition=fundamental","pubTime":"2026-03-31 12:08","pubTimestamp":1774930126,"startTime":"0","endTime":"0","summary":"Racura Oncology  said the first patient was recruited to its phase 1 HARNESS-1 clinical trial of its cancer drug candidate RC220 in patients with non-small cell lung cancer with activated epidermal growth factor receptor  mutations being treated with osimertinib, according to a Tuesday Australian bourse filing.The company said the trial aims to address the significant unmet medical need of preventing or delaying resistance to standard-of-care EGFR-mutant tyrosine kinase inhibitors such as osimertinib, with four additional clinical trial sites expected to be activated in the coming months.RC220 is an experimental oral drug candidate designed to inhibit the proto-oncogene tyrosine-protein kinase  protein, which is believed to drive resistance to EGFR-targeted therapies.The trial aims to test whether combining RC220 with osimertinib can prevent or delay tumors from developing resistance to the standard-of-care treatment, the filing added.The company's shares rose 2% in recent Tuesday trad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","RAC.AU","BK7067","BK4080","BK4231","SRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622886879","title":"BUZZ-Australia's Racura Oncology gains on Purdue University cancer study collab","url":"https://stock-news.laohu8.com/highlight/detail?id=2622886879","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622886879?lang=en_us&edition=fundamental","pubTime":"2026-03-26 08:30","pubTimestamp":1774485045,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Racura Oncology gains on Purdue University cancer study collab** Racura Oncology RAC.AX rises as much as 4% to A$2.85, highest since March 25** Biopharma co commences research collabo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL6N40E00Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","RAC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620297546","title":"Why EBR, EOS, Racura, and Woodside shares are rising today","url":"https://stock-news.laohu8.com/highlight/detail?id=2620297546","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620297546?lang=en_us&edition=fundamental","pubTime":"2026-03-19 10:13","pubTimestamp":1773886413,"startTime":"0","endTime":"0","summary":"In afternoon trade, theS&P/ASX 200 Index  is out of form and sinking deep into the red. At the time of writing, the benchmark index is down 1.5% to 8,508.3 points.Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:. The EOS share price is up a further 3% to $10.01. This defence and space company's shares have been rebounding after a majorsell-off on Tuesday. The catalyst for this was news that the company's CEO, Dr Andreas Schwer, was given approval to sell 2.5 million EOS shares on-market following the exercise of options that were granted under a long-term incentive plan. Some investors may believe the selling was an overreaction, especially after its CEO committed to retain a shareholding well above the minimum levels required under its recently announced shareholding policy.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/19/why-ebr-eos-racura-and-woodside-shares-are-rising-today/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/19/why-ebr-eos-racura-and-woodside-shares-are-rising-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7115","EOS.AU","RAC.AU","BK7508","EBR.AU","EOS","BK7142","WDS.AU","XJO.AU","BK7067","BK7007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620296228","title":"Racura Oncology Says Recruitment of First Trial Group in Phase One Advanced Solid Tumors Clinical Trial Completed, Shares Jump 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620296228","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620296228?lang=en_us&edition=fundamental","pubTime":"2026-03-19 07:56","pubTimestamp":1773878164,"startTime":"0","endTime":"0","summary":"Racura Oncology  said a third patient in its CPACS phase one clinical trial in advanced solid tumors was dosed with 40 milligrams per square meter of RC220, its proprietary formulation of bisantrene, at the first Hong Kong site, completing the recruitment of the first trial group, according to a Thursday Australian bourse filing.No phlebitis or any other adverse events were reported following the dosing. The safety review committee will review all accumulated safety data collected from the three patients.The first stage of the trial is using ascending doses of the drug candidate to determine the safety, tolerability, pharmacokinetics, and maximum tolerated combined dose of RC220 in combination with doxorubicin in up to 33 patients. The effects on a range of clinical biomarkers, including a blood-based measure of the cardioprotective mechanism of action of RC220, will also be examined.Its shares jumped 12% in recent trading on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","AEIS","RAC.AU","IE0031619046.USD","IE00B7SZL793.SGD","LU0757428866.USD","BK7067","IE00B19Z4B17.USD","IE00B66KJ199.SGD","BK4157","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620296185","title":"Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620296185","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620296185?lang=en_us&edition=fundamental","pubTime":"2026-03-19 07:42","pubTimestamp":1773877328,"startTime":"0","endTime":"0","summary":"Shares in Racura Oncology Ltd (ASX: RAC) have jumped more than 10% in early trade after the company announced the successful first dosing of a patient in Hong Kong with its RC220 cancer compound.  The","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/19/which-asx-biotechs-shares-have-jumped-more-than-10-on-positive-clinical-trial-news/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/19/which-asx-biotechs-shares-have-jumped-more-than-10-on-positive-clinical-trial-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["RAC.AU","BK4231","BK7067","BK7508","BK4080","SRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619190482","title":"Racura Oncology Secures Governance Approval For Phase One Trial Testing Its Proprietary Formulation For Non-Small Cell Lung Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2619190482","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619190482?lang=en_us&edition=fundamental","pubTime":"2026-03-16 09:23","pubTimestamp":1773624182,"startTime":"0","endTime":"0","summary":"Racura Oncology  received governance approval from Monash Health for its phase one clinical trial assessing the safety, tolerability, and pharmacokinetics of RC220, its proprietary formulation of bisantrene, in combination with osimertinib, in patients with non-small cell lung cancer who have activating epidermal growth factor receptor mutations, according to a Monday Australian bourse filing.Osimertinib is the current standard of care treatment for non-small cell lung cancer with defined epidermal growth factor receptor mutations, the company said in an earlier filing.Teams from Racura Oncology, Monash Health, and Contract Research Organisation Beyond Drug Development will meet at Monash Medical Centre in Clayton, Victoria, for site initiation and training on March 23. This will allow the first patients to be recruited into the trial.The secondary and exploratory endpoints include progression-free survival, overall survival, changes in levels of circulating tumor DNA, and changes in t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619827334","title":"Monday’s HotCopper trends: Elixir, Lynas, Racura, and other daily topics | March 16","url":"https://stock-news.laohu8.com/highlight/detail?id=2619827334","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619827334?lang=en_us&edition=fundamental","pubTime":"2026-03-16 09:14","pubTimestamp":1773623640,"startTime":"0","endTime":"0","summary":"Energy, materials, and health care are all getting a run at the top of the HotCopper forums, with each of the top three managing to stay above what was a pretty red open Monday .Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.First up, Elixir Energy  has got chins wagging by landing an “exceptional” outcome in the final drilling results of the Lorelle-3H appraisal well within Queensland’s Taroom Trough. The well hit 1,033m of high-quality net gas-condensate pay within the targeted Tinowon ‘Dunk’ sandstone, which is now being described as one of the highest impact wells to be drilled in the trough this year.Racura Oncology  brought up the rear in the top three on HotCopper today. The ever-popular healthcare company received governance approval from Monash Health for the HARNESS-1 Phase 1 trial of RC220 in EGFR non-small cell lung cancer patients being treated with osimertinib.And loo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"markerherald_stock","url":"https://themarketonline.com.au/mondays-hotcopper-trends-elixir-lynas-racura-and-other-daily-topics-march-16-2026-03-16/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/mondays-hotcopper-trends-elixir-lynas-racura-and-other-daily-topics-march-16-2026-03-16/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["EXR.AU","BK7095","BK7508","LYC.AU","BK7507","BK7142","BK7067","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619484771","title":"BRIEF-Racura Oncology Receives Governance Approval For Harness-1 Phase 1 Trial Of Rc220","url":"https://stock-news.laohu8.com/highlight/detail?id=2619484771","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619484771?lang=en_us&edition=fundamental","pubTime":"2026-03-16 09:08","pubTimestamp":1773623280,"startTime":"0","endTime":"0","summary":"BRIEF-Racura Oncology Receives Governance Approval For Harness-1 Phase 1 Trial Of Rc220March 16 (Reuters) - Racura Oncology Ltd RAC.AX:RECEIVES GOVERNANCE APPROVAL FOR HARNESS-1 PHASE 1 TRIAL OF RC220Further company coverage: RAC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN40200N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619485234","title":"Racura Oncology  - Receives Governance Approval for Harness-1 Phase 1 Trial of Rc220","url":"https://stock-news.laohu8.com/highlight/detail?id=2619485234","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619485234?lang=en_us&edition=fundamental","pubTime":"2026-03-16 05:56","pubTimestamp":1773611808,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260315:nFWN40200N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610967768","title":"Racura Oncology Develops Blood Test to Assess Potential of Proprietary Formulation of Anticancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2610967768","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610967768?lang=en_us&edition=fundamental","pubTime":"2026-02-11 07:19","pubTimestamp":1770765542,"startTime":"0","endTime":"0","summary":"Racura Oncology  developed a blood-based molecular test to assess the potential of RC220, its proprietary formulation of bisantrene, a potent anticancer drug, to protect the heart from damage, according to a Wednesday filing with the Australian bourse.The blood test will quantify the protective effects of RC220 on the molecular pathways causing anthracycline cardiotoxicity, a side effect of chemotherapy, the filing said.Bisantrene has proven clinical efficacy in a range of solid tumor cancers with lower heart toxicity than other widely used chemotherapies, the company said in a statement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609555609","title":"Racura Oncology Proposes Selective Buyback, Cancellation Of Shares After Administrative Oversight in Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2609555609","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609555609?lang=en_us&edition=fundamental","pubTime":"2026-02-06 13:11","pubTimestamp":1770354705,"startTime":"0","endTime":"0","summary":"Racura Oncology  is proposing to conduct a selective buyback and cancellation of its shares, subject to shareholder approval at its annual general meeting, after an aggregate of 179,242 additional shares were issued to its Chief Executive Officer Daniel Tillett and former CEO Phillip Lynch, and recorded on the Company's share register, rather than the intended number of 761,828 shares, due to an administrative oversight, according to a Friday Australian bourse filing.It issued 941,090 ordinary shares on Nov. 21, 2025, on the cashless exercise of 4 million unlisted options with an exercise price of AU$2.65 per share expiring Nov. 29, 2025, issued to Tillett and Lynch.The Options were issued to Tillett and Lynch under the company's employee securities incentive plan approved by shareholders at the 2018 Annual General Meeting and were exercised into shares using the cashless exercise facility under that plan.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":38,"code":"91000000","status":"200"}]}}